Straits Times Index
3,215.40 +10.58 (+0.33%) S&P 500
4,320.06 -9.94 (-0.23%) Dow
33,963.84 -106.56 (-0.31%) Nasdaq
13,211.81 -12.19 (-0.09%) Bitcoin USD
26,116.49 -483.78 (-1.82%) CMC Crypto 200
558.26 -9.79 (-1.72%)
Coherus BioSciences, Inc. (CHRS)
Pre-market:
| Previous close | 4.1400 |
| Open | 4.1500 |
| Bid | 4.3100 x 4000 |
| Ask | 4.4300 x 2200 |
| Day's range | 4.1400 - 4.4750 |
| 52-week range | 3.6000 - 10.9910 |
| Volume | |
| Avg. volume | 3,005,612 |
| Market cap | 474.499M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Why Coherus BioSciences Stock Was Plunging This Week
Unfortunately for shareholders of Coherus BioSciences (NASDAQ: CHRS), that's what happened to their company after market hours last Friday. Following that, its stock price was falling by 10% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence. Among these incoming S&P SmallCap 600 constituents are pizza slinger Papa John's International, storied athletic apparel retailer Foot Locker, and JetBlue Airways.
- Motley Fool
Why Coherus BioSciences Stock Popped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) soared 17.7% on Thursday, according to data provided by S&P Global Market Intelligence, after the biotech company announced better-than-expected quarterly results. Coherus' net revenue climbed a whopping 81% year over year to $58.7 million, translating to an adjusted net loss of $32.8 million, or $0.38 per share. Analysts, on average, were anticipating a wider net loss of $0.48 per share on lower revenue of $50.5 million.
- Zacks
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 26.92% and 15.53%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
